224 related articles for article (PubMed ID: 32881299)
1. EEF1A2 and ERN2 could potentially discriminate metastatic status of mediastinal lymph node in lung adenocarcinomas harboring EGFR 19Del/L858R mutations.
Xia L; Wang H; Xiao H; Lan B; Liu J; Yang Z
Thorac Cancer; 2020 Oct; 11(10):2755-2766. PubMed ID: 32881299
[TBL] [Abstract][Full Text] [Related]
2. Are exon 19 deletions and L858R different in early stage lung adenocarcinoma?
Zhang Y; Ma Y; Li Y; Shen X; Yu Y; Pan Y; Zhang Y; Yu S; Zheng D; Zhao Y; Hu H; Sun Y; Zhang Y; Xiang J; Chen H
J Cancer Res Clin Oncol; 2018 Jan; 144(1):165-171. PubMed ID: 29026990
[TBL] [Abstract][Full Text] [Related]
3. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
4. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475
[TBL] [Abstract][Full Text] [Related]
5. Comparison of therapeutic effects of EGFR-tyrosine kinase inhibitors on 19Del and L858R mutations in advanced lung adenocarcinoma and effect on cellular immune function.
Zhou J; Ben S
Thorac Cancer; 2018 Feb; 9(2):228-233. PubMed ID: 29222872
[TBL] [Abstract][Full Text] [Related]
6. Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis.
Zhang S; Yan B; Zheng J; Zhao J; Zhou J
Oncotarget; 2016 Sep; 7(39):63758-63766. PubMed ID: 27563816
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implication of EGFR mutation status and subtype in resected lung adenocarcinoma patients irrespective of therapy.
Li R; Li Q; Lin S; Li W; Yu L; Wang L; Dong X; Yu L; Li S; Liu W; Li B
Clin Transl Oncol; 2019 Mar; 21(3):298-303. PubMed ID: 30022385
[TBL] [Abstract][Full Text] [Related]
8. Significance of the epidermal growth factor receptor mutation status and differences among molecular subgroups in surgically resected lung microinvasive adenocarcinoma.
Li M; Li C; Ke L; Zhan M; Cheng M
Oncol Lett; 2018 Dec; 16(6):7057-7067. PubMed ID: 30546439
[TBL] [Abstract][Full Text] [Related]
9. [Relationship between histopathologic characteristics and epidermal growth factor receptor mutation in lung adenocarcinoma].
Wang K; Gong H; Li X; Yang Z; Cao P; Wand C; Jiang Y; Wang H; Wang Y; Zhang G
Zhonghua Bing Li Xue Za Zhi; 2015 Mar; 44(3):170-4. PubMed ID: 26268750
[TBL] [Abstract][Full Text] [Related]
10. Occult mediastinal lymph node metastasis in FDG-PET/CT node-negative lung adenocarcinoma patients: Risk factors and histopathological study.
Miao H; Shaolei L; Nan L; Yumei L; Shanyuan Z; Fangliang L; Yue Y
Thorac Cancer; 2019 Jun; 10(6):1453-1460. PubMed ID: 31127706
[TBL] [Abstract][Full Text] [Related]
11. Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study.
Zhou J; Qin H; Miao J; Liu R; Wang W
Medicine (Baltimore); 2023 Jun; 102(26):e34110. PubMed ID: 37390279
[TBL] [Abstract][Full Text] [Related]
12. Epidermal Growth Factor Receptor Mutation Detection in Cerebrospinal Fluid of Lung Adenocarcinoma Patients with Leptomeningeal Metastasis.
Huang R; Ge M; Zhou X; Ji X; Liao L; Liang X; Zhan Q
Cancer Biother Radiopharm; 2019 Mar; 34(2):128-133. PubMed ID: 30452286
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis.
Qu J; Wang YN; Xu P; Xiang DX; Yang R; Wei W; Qu Q
Oncotarget; 2017 May; 8(20):33961-33971. PubMed ID: 28430623
[TBL] [Abstract][Full Text] [Related]
14. Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples.
Fan X; Liu B; Xu H; Yu B; Shi S; Zhang J; Wang X; Wang J; Lu Z; Ma H; Zhou X
Hum Pathol; 2013 Aug; 44(8):1499-507. PubMed ID: 23465272
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological characteristics of lung adenocarcinoma with compound EGFR mutations.
Hayashi T; Kohsaka S; Takamochi K; Hara K; Kishikawa S; Sano K; Takahashi F; Suehara Y; Saito T; Takahashi K; Suzuki K; Yao T
Hum Pathol; 2020 Sep; 103():42-51. PubMed ID: 32673682
[TBL] [Abstract][Full Text] [Related]
16. The incidence and distribution of mediastinal lymph node metastasis and its impact on survival in patients with non-small-cell lung cancers 3 cm or less: data from 2292 cases.
Yang MZ; Hou X; Liang RB; Lai RC; Yang J; Li S; Long H; Fu JH; Lin P; Wang X; Rong TH; Yang HX
Eur J Cardiothorac Surg; 2019 Jul; 56(1):159-166. PubMed ID: 30668665
[TBL] [Abstract][Full Text] [Related]
17. Concomitant Mutations in EGFR 19Del/L858R Mutation and Their Association with Response to EGFR-TKIs in NSCLC Patients.
Liang H; Li C; Zhao Y; Zhao S; Huang J; Cai X; Cheng B; Xiong S; Li J; Wang W; Zhu C; Li W; He J; Liang W
Cancer Manag Res; 2020; 12():8653-8662. PubMed ID: 32982456
[TBL] [Abstract][Full Text] [Related]
18. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
[TBL] [Abstract][Full Text] [Related]
19. Epidermal Growth Factor Receptor Gene Mutation Status in Primary Lung Adenocarcinoma and Corresponding Bone Metastases.
Shi PX; Li YT; Wang SY; Sun RZ; Xu HT; Dong QZ; Zhao Y; Wang EH; Liu Y
Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):49-56. PubMed ID: 30601156
[TBL] [Abstract][Full Text] [Related]
20. Radiomics for the prediction of EGFR mutation subtypes in non-small cell lung cancer.
Li S; Ding C; Zhang H; Song J; Wu L
Med Phys; 2019 Oct; 46(10):4545-4552. PubMed ID: 31376283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
